Spyre Therapeutics Is Maintained at Buy by Guggenheim
Spyre Therapeutics Analyst Ratings
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Promising Advancements in Spyre Therapeutics' Programs Drive Buy Rating
Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Wells Fargo Issues a Buy Rating on Spyre Therapeutics (SYRE)
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Spyre Therapeutics Analyst Ratings
Wedbush Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $45
Analysts' Top Healthcare Picks: PMV Pharmaceuticals (PMVP), Spyre Therapeutics (SYRE)
TD Cowen Remains a Buy on Spyre Therapeutics (SYRE)
Spyre Therapeutics Analyst Ratings
Spyre Therapeutics Analyst Ratings
Buy Rating Affirmed: Spyre Therapeutics' Promising Pipeline and Expert Team Drive Positive Outlook
Spyre Therapeutics Analyst Ratings
BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $40
Spyre Therapeutics (SYRE.US) was first covered by Baird, which gave it an superior market rating and a target price of $50.00.